Keeping in mind that these studies did not report any biomarker data associated with ameliorating disease but, given that melatonin is an over-the- counter medication, relatively inexpensive, and is also endogenously produced, patients with AD and APOE ɛ4 carriers could consider this substance as a low-risk potential co-treatment strategy. The gene discussed is APOE; the disease is Alzheimer disease.